Elemene displays anti-cancer ability on laryngeal cancer cells in vitro and in vivo

Original Article

Abstract

Purpose: The goal of this study is to investigate the inhibitory effects and mechanism of elemene on the growth of laryngeal cancer cells in vitro and in vivo. Methods: Laryngeal cancer cells (HEp-2 cells) were grown in elemene, cisplatin, or a combination of the drugs. The cytotoxic, or apoptotic, effects of elemene on the cells were evaluated by a 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide assay, flow cytometry, and a caspase-3 activity assay. A Western blot was used to semi-quantify the protein expression of eukaryotic initiation factors (eIF4E and eIF4G), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF); RT-PCR analysis semi-quantified the mRNA transcript expression of bFGF and VEGF. The HEp-2 cells were transplanted subcutaneously to BALB/c nude mice to produce solid tumors. Elemene and cisplatin were administered to the mice either as individual drugs or in combination. The tumors were excised and immunostained to determine the effect each drug had on tumor size, eIF levels, angiogenic factors, and microvessel density (MVD). Results: Elemene inhibited the growth of HEp-2 cells in vitro in a dose- and time-dependent manner with an IC50 of 346.5 μM (24 h incubation). Increased apoptosis was observed in elemene-administered cells. Elemene is suspected to enhance caspase-3 activity, and thus inhibit protein expression of eIFs (4E, 4G), bFGF, and VEGF. In vivo, the growth of HEp-2 cell-transplanted tumors in nude mice was inhibited by intraperitoneal injection of elemene. Compared with control groups, elemene significantly inhibited the protein expression of eIFs (4E and 4G), bFGF, and VEGF and decreased the MVD. Conclusions: Elemene inhibits the growth of HEp-2 cells in vitro and in vivo. These data provide useful information for further clinical study on the treatment of LSCC by elemene.

Keywords

Elemene Laryngeal squamous cell carcinoma Apoptosis EIF Angiogenesis 

Abbreviations

A

Absorbances

BFGF

Basic fibroblast growth factor

DAB

3,3′-diaminobenzidine tetrahydrochloride

EIF

Eukaryotic initiation factor

GI

Growth inhibition

IR

Inhibition rate

LSCC

Laryngeal squamous cell carcinoma

MVD

Microvessel density

PI

Propidium iodide

PNA

P-nitroanalide

VEGF

Vascular endothelial growth factor

References

  1. 1.
    Colasanto JM, Haffty BG, Wilson LD (2004) Evaluation of local recurrence and second malignancy in patients with T1 and T2 squamous cell carcinoma of the larynx. Cancer J 10:61–66PubMedCrossRefGoogle Scholar
  2. 2.
    Moyer JS, Wolf GT, Bradford CR (2004) Current thoughts on the role of chemotherapy and radiation in advanced head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 12:82–87PubMedCrossRefGoogle Scholar
  3. 3.
    Weise JB, Maune S, Gorogh T, Kabelitz D, Arnold N, Pfisterer J, Hilpert F, Heiser A (2004) A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC. Auris Nasus Larynx 31:149–153PubMedCrossRefGoogle Scholar
  4. 4.
    Kroep JR, Peters GJ, van Moorsel CJ, Catik A, Vermorken JB, Pinedo HM, van Groeningen CJ (1999) Gemcitabine-cisplatin: a schedule finding study. Ann Oncol 10:1503–1510PubMedCrossRefGoogle Scholar
  5. 5.
    Hitt R, Jimeno A, Millan JM, Castellano D, Cortes-Funes H (2004) Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Cancer 101:768–775PubMedCrossRefGoogle Scholar
  6. 6.
    Zheng S, Yang H, Zhang S, Wang X, Yu L, Lu J, Li J (1998) Initial study on naturally occurring products from traditional Chinese herbs and vegetables for chemoprevention. J Cell Biochem 67:106–112CrossRefGoogle Scholar
  7. 7.
    Chen SL, You J, Wang GJ (2001) Supercritical fluid extraction of beta-elemene under lower pressure. Se Pu 19:179–181PubMedGoogle Scholar
  8. 8.
    Zheng S, Yang H, Zhang S, Wang X, Yu L, Lu J, Li J (1997) Initial study on naturally occurring products from traditional Chinese herbs and vegetables for chemoprevention. J Cell Biochem Suppl 27:106–112PubMedCrossRefGoogle Scholar
  9. 9.
    Yang H, Wang X, Yu L (1996) The antitumor activity of elemene is associated with apoptosis. Zhonghua Zhong Liu Za Zhi 18:169–172PubMedGoogle Scholar
  10. 10.
    Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR, Martin SJ (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 144:281–292PubMedCrossRefGoogle Scholar
  11. 11.
    Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD (2001) Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 61:348–354PubMedGoogle Scholar
  12. 12.
    Gupta S (2001) Molecular steps of death receptor and mitochondrial pathways of apoptosis. Life Sci 69:2957–2964PubMedCrossRefGoogle Scholar
  13. 13.
    Clemens MJ, Bushell M, Jeffrey IW, Pain VM, Morley SJ (2000) Translation initiation factor modifications and the regulation of protein synthesis in apoptotic cells. Cell Death Differ 7:603–615PubMedCrossRefGoogle Scholar
  14. 14.
    De Benedetti A, Harris AL (1999) eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Bio 31:59–72CrossRefGoogle Scholar
  15. 15.
    Fukuchi-Shimogori T, Ishii I, Kashiwagi K, Mashiba H, Ekimoto H, Igarashi K (1997) Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res 57:5041–5044PubMedGoogle Scholar
  16. 16.
    McKendrick L, Pain VM, Morley SJ. Translation initiation factor 4E (1999) Int J Biochem Cell Bio 31:31–35CrossRefGoogle Scholar
  17. 17.
    Zhang K, Chew M, Yang EB, Wong KP, Mack P (2001) Modulation of cisplatin cytotoxicity and cisplatin-induced DNA interstrand cross-links by regulation of glutathione related mechanisms. Mol Pharmacol 59:837–843PubMedGoogle Scholar
  18. 18.
    Evens AM, Prachand S, Shi B, Paniaqua M, Gordon LI, Gartenhaus RB (2004) Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. Clin Cancer Res 10:1481–1491PubMedCrossRefGoogle Scholar
  19. 19.
    Muzio M, Salvesen GS, Dixit VM (1997) FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. J Biol Chem 272:2952–2956PubMedCrossRefGoogle Scholar
  20. 20.
    Zhou L, Tao L, Zheng LY, Gao YP (2003) The expression of proto-oncogene eIF4E in laryngeal squamous cell carcinoma. Laryngoscope 113:1238–1243CrossRefGoogle Scholar
  21. 21.
    Nanda GS, Sun FX, Hofmann GA, Hoffman RM, Dev SB (1998) Electroporation therapy of human larynx tumors HEp-2 implanted in nude mice. Anticancer Res 18:999–1004PubMedGoogle Scholar
  22. 22.
    Zhang K, Chow PK (2004) The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo. Clin Cancer Res 10:5226–5232PubMedCrossRefGoogle Scholar
  23. 23.
    Pavelic Z, Pavelic K, Cater C, Pavelic L (1992) Heterogeneity of c-myc expression in histologically similar infiltrating ductal carcinomas of the breast. J Cancer Res Clin Oncol 118:16–22PubMedCrossRefGoogle Scholar
  24. 24.
    Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R, Huang S (2005) Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 11:1386–1393PubMedCrossRefGoogle Scholar
  25. 25.
    Baskota DK, Prasad R, Sinha BK, Amatya RC, Bhattarai H, Guragain RP (2004) Outcome of surgical management of laryngeal carcinoma: a 5-year experience. Acta Otolaryngol 124:739–743PubMedCrossRefGoogle Scholar
  26. 26.
    Jazirehi AR, Bonavida B (2005) Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24:2121–2143PubMedCrossRefGoogle Scholar
  27. 27.
    Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R (2005) Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23:2145–2154PubMedCrossRefGoogle Scholar
  28. 28.
    Douer D, Tallman MS (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23:2396–2410PubMedCrossRefGoogle Scholar
  29. 29.
    Hu J, Jin W, Yang PM (2004) Reversal of resistance to adriamycin in human breast cancer cell line MCF-7/ADM by beta-elemene. Zhonghua Zhong Liu Za Zhi 26:268–270PubMedGoogle Scholar
  30. 30.
    Zhou HY, Shen JK, Hou JS, Qiu YM, Luo QZ (2003) Experimental study on apoptosis induced by elemene in glioma cells. Ai Zheng 22:959–963PubMedGoogle Scholar
  31. 31.
    Bier H, Bergler W, Mickisch G, Wesch H, Ganzer U (1990) Establishment and characterization of cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79. Acta Otolaryngol 110:466–473PubMedGoogle Scholar
  32. 32.
    Engbers-Buijtenhuijs P, Kamphuis M, van der Sluijs Veer G, Haanen C, Poot AA, Feijen J, Vermes I (2005) A novel time resolved fluorometric assay of anoikis using Europium-labelled Annexin V in cultured adherent cells. Apoptosis 10:429–437PubMedCrossRefGoogle Scholar
  33. 33.
    Pulkkinen JO, Elomaa L, Joensuu H, Martikainen P, Servomaa K, Grenman R (1996) Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. J Cancer Res Clin Oncol 122:214–218PubMedCrossRefGoogle Scholar
  34. 34.
    Fujita E, Egashira J, Urase K, Kuitda K, Momoi T (2001) Caspase-9 processing by caspase-3 via a feedback amplification loop in vivo. Cell Death Differ 8:335–344PubMedCrossRefGoogle Scholar
  35. 35.
    Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA (2002) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37–43CrossRefGoogle Scholar
  36. 36.
    Wang X, Zelenski NG, Yang J, Sakai J, Brown MS, Goldstein JL (1996) Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis. EMBO J 15:1012–1020PubMedGoogle Scholar
  37. 37.
    Liu B, Hannun YA (1997) Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem 272:16281–16287PubMedCrossRefGoogle Scholar
  38. 38.
    Casciola-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, Miller DK, Rosen A (1996) Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principal of apoptotic death. J Exp Med 183:1957–1964PubMedCrossRefGoogle Scholar
  39. 39.
    Liu L, Simon MC (2004) Regulation of transcription and translation by hypoxia. Cancer Biol Ther 3:492–427PubMedGoogle Scholar
  40. 40.
    von Der Haar T, Ball PD, McCarthy JE (2000) Stabilization of eukaryotic initiation factor 4E binding to the mRNA 5’-Cap by domains of eIF4G. J Biol Chem 275:30551–30555CrossRefGoogle Scholar
  41. 41.
    Scheper GC, Proud CG (2002) Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation? Eur J Biochem 269:5350–5359PubMedCrossRefGoogle Scholar
  42. 42.
    Prevot D, Darlix JL, Ohlmann T (2003) Conducting the initiation of protein synthesis: the role of eIF4G. Biol Cell 95:141–156PubMedCrossRefGoogle Scholar
  43. 43.
    Tee AR, Proud CG (2002) Caspase cleavage of initiation factor 4E-binding protein 1 yields a dominant inhibitor of cap-dependent translation and reveals a novel regulatory motif. Mol Cell Biol 22:1674–1683PubMedCrossRefGoogle Scholar
  44. 44.
    Bushell M, McKendrick L, Janicke RU, Clemens MJ, Morley SJ (1999) Caspase-3 is necessary and sufficient for cleavage of protein synthesis eukaryotic initiation factor 4G during apoptosis. FEBS Lett 451:332–336PubMedCrossRefGoogle Scholar
  45. 45.
    Sivan HK, Naomi LS, Dan G, Adi K (2000) A novel form of DAP5 protein accumulates in apoptotic cells as a result of caspase cleavage and internal ribosome entry site-mediated translation. Mol Cell Biol 20:496–506CrossRefGoogle Scholar
  46. 46.
    Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF (1999) Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5:1041–1056PubMedGoogle Scholar
  47. 47.
    Lund EL, Thorsen C, Pedersen MW, Junker N, Kristjansen PE (2000) Relationship between vessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro. Clin Cancer Res 6:4287–4291PubMedGoogle Scholar
  48. 48.
    Pignataro L, Carboni N, Midolo V, Bertolini F, Buffa R, Cesana BM, Neri A, Viale G, Pruneri G (2001) Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. Int J Cancer 92:666–670PubMedCrossRefGoogle Scholar
  49. 49.
    Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM (2000) Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89:488–499PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Department of otolaryngology-HNSEye, Ear, Nose and Throat Hospital of Fudan UniversityShanghaiChina
  2. 2.Department of PathologyRenji Hospital of Shanghai Second Medical UniversityShanghaiChina
  3. 3.Department of Experiment and PathologyShanghai Cancer InstituteShanghaiChina

Personalised recommendations